Bimeda to Become Exclusive Distributor of EquellT and EquimaxT

OAKBROOK, Illinois and CAMBRIDGE, Ontario (October 1, 2009) – Bimeda announced it will become the exclusive U.S. and Canadian distributor of, EquellT (ivermectin) Paste and EquimaxT (ivermectin praziquantel) Paste, manufactured by Virbac Corporation, effective today.

Both products complement the growing line of equine products already marketed by Bimeda in the United States, including BimectinR (ivermectin) Paste 1.87% and ExodusR (pyrantel pamoate) Paste anthelmintics. Additional products within Bimeda’s equine category include ButatronR(phenylbutazone) Tablets, DexiumR (dexamethasone) 2mg/mL Injection, DexiumR-SPT (dexamethasone sodium phosphate 4 mg), FlunazineR (flunixin meglumine) Injectable Solution, Fura-SeptinT (Nitrofurazone) Ointment, Hypertonic Saline Solution 7.2%, Lactated Ringer’s Injection, USP and Pro-Pen-GR (Penicillin G procaine) Suspension.

Pfizer Animal Health and Virbac had previously co-marketed and distributed Equell and Equimax in the U.S. and Canada. Pfizer moved to divest these products as part of Pfizer’s previously announced decision to divest certain animal health assets in connection with the regulatory approval process associated with Pfizer’s pending acquisition of Wyeth.

Pfizer Animal Health will continue to honor all current programs that include Equell and Equimax, including the PreventiCareT program in the U.S. for the duration of customers’ contracts

About Bimeda

Bimeda, Inc. is a leading manufacturer of a variety of novel and generic animal health pharmaceutical dosage forms produced in three FDA approved manufacturing plants throughout North America. The company is headquartered in Oakbrook Terrace, IL.

For more information, visit www.bimedaus.com in the U.S. or www.bimedamtc.com in Canada.